Severe Asthma
Mepolizumab reduces asthma exacerbations, expenditures in patients with history of high cost
Among patients with severe asthma and the highest expenditures prior to treatment, mepolizumab reduced asthma exacerbations, oral corticosteroid use and related costs, according to research presented at the CHEST Annual Meeting.
Risankizumab fails to outperform placebo in severe asthma treatment
Risankizumab appeared to worsen severe asthma symptoms compared with placebo, according to results of a randomized phase 2a study published in The New England Journal of Medicine.
Itepekimab lowers events indicating loss of asthma control, improves lung function
Treatment with itepekimab resulted in a lower incidence of events indicating loss of asthma control and improved lung function in adults with moderate to severe asthma, according to new phase 2 data.
FDA approves dupilumab for children aged 6 to 11 with moderate to severe asthma
The FDA has approved dupilumab as an add-on maintenance treatment for children aged 6 to 11 years with moderate to severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma.
Report: Tezepelumab reduces severe asthma exacerbations, but unlikely to be cost-effective
Tezepelumab reduces exacerbations among patients who have severe asthma, including some types of asthma that lack other effective biologic therapies, according to a draft evidence report by the Institute for Clinical and Economic Review.
Benralizumab shows real-world efficacy for severe asthma regardless of nasal polyps
Benralizumab appeared effective for severe eosinophilic asthma in a real-world study of patients with and without chronic rhinosinusitis with nasal polyps, according to data published in The Journal of Allergy and Clinical Immunology.
Dexpramipexole reduces eosinophils, improves lung function in moderate to severe asthma
In patients with moderate to severe eosinophilic asthma, treatment with dexpramipexole depleted blood and tissue eosinophils, which correlated with improvement in lung function, according to results of the phase 2 EXHALE trial.
New clinical underway to use personalized medicine to treat severe asthma
A new phase 2 clinical trial of multiple therapies to treat patients with severe asthma, specifically focusing on personalized therapies based on genetics, family history, lifestyle and environmental factors, is currently underway.
VIDEO: New data on dupilumab in children with uncontrolled moderate to severe asthma
In this video, Leonard B. Bacharier, MD, presents results of the LIBERTY ASTHMA VOYAGE trial, which evaluated dupilumab in children aged 6 to 11 years with uncontrolled moderate to severe asthma with evidence of type 2 inflammation.
Triple therapy reduces exacerbations, improves control in moderate to severe asthma
Triple therapy, compared with dual therapy, was associated with fewer asthma exacerbations and modest improvements in asthma control in children and adults with moderate to severe asthma, according to a new meta-analysis.